Table 3

 Selected characteristics of studies investigating commercial tests for the diagnosis of extrapulmonary tuberculosis

ReferenceData collectionVerificationReference standardDisease siteCountryComparison groupName of test*No. of participants‡Sensitivity (95% CI)Specificity (95% CI)
NR, not reported.
*All commercial tests detected immunoglobulin G antibody.
†Blinded study.
‡Number of participants with tuberculosis/without tuberculosis.
Banerjee(2003, b)42RetrospectiveNRHistologyLymph nodeIndiaHealthySEVA TB30/320.77 (0.58 to 0.90)0.88 (0.71 to 0.97)
McConkey(2002)48ProspectiveCompleteCultureMeningesEgyptMixed diseaseAMRAD ICT56/740.48 (0.35 to 0.62)0.82 (0.72 to 0.90)
Nsanze(1997, a)49ProspectiveDifferentialCulture and/or smearNRUAEMixed disease and healthyPathozyme Myco35/350.51 (0.34 to 0.69)1.00 (0.90 to 1.00)
Nsanze(1997, b)49ProspectiveDifferentialCulture and/or smearNRUAEMixed disease and healthyPathozyme TB Complex Plus35/350.11 (0.03 to 0.27)1.00 (0.90 to 1.00)